A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea
NCT ID: NCT00034294
Last Updated: 2015-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2002-02-28
2003-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
NCT00196794
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
NCT00106509
Study of CB-183,315 in Participants With Clostridium Difficile Infection
NCT01085591
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
NCT03824795
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
NCT03462459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GT160-246
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have active mild to moderate C. difficile- Associated Diarrhea (CDAD).
* Be able to tolerate oral medication.
* Not be pregnant or breast-feeding.
* Sign and date an informed consent form.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Genzyme, a Sanofi Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Sacramento, California, United States
Newark, Delaware, United States
Bay Pines, Florida, United States
Brandon, Florida, United States
Hollywood, Florida, United States
Naples, Florida, United States
Orlando, Florida, United States
Austell, Georgia, United States
Columbus, Georgia, United States
Chicago, Illinois, United States
Maywood, Illinois, United States
North Chicago, Illinois, United States
Columbus, Indiana, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Wichita, Kansas, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Chevy Chase, Maryland, United States
Boston, Massachusetts, United States
Braintree, Massachusetts, United States
West Roxbury, Massachusetts, United States
Springfield, Missouri, United States
St Louis, Missouri, United States
Stratford, New Jersey, United States
Buffalo, New York, United States
Jamaica, New York, United States
Manhasset, New York, United States
New York, New York, United States
New York, New York, United States
Syracuse, New York, United States
Asheville, North Carolina, United States
Charlotte, North Carolina, United States
Fargo, North Dakota, United States
Columbus, Ohio, United States
Toledo, Ohio, United States
Oklahoma City, Oklahoma, United States
Allentown, Pennsylvania, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Upland, Pennsylvania, United States
Charleston, South Carolina, United States
Clarksville, Tennessee, United States
Memphis, Tennessee, United States
Temple, Texas, United States
Falls Church, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Seattle, Washington, United States
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Moncton, New Brunswick, Canada
Ottawa, Ontario, Canada
Windsor, Ontario, Canada
Chicoutimi, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Trois-Rivières, Quebec, Canada
Hato Rey, , Puerto Rico
Heathpark, Cardiff, United Kingdom
Penlan Rd, Cardiff, United Kingdom
Steeton, Keighley, United Kingdom
Bury, Lancashire, United Kingdom
Chelsea, London, United Kingdom
South Kensington, London, United Kingdom
High Heaton, Newcastle-upon-Tyne, United Kingdom
Cliftonville, Northampton, United Kingdom
Fulwood, Preston, United Kingdom
Livilands, Stirling, United Kingdom
Morriston, Swansea, United Kingdom
Birmingham, , United Kingdom
Birmingham, , United Kingdom
Cambridge, , United Kingdom
Edinburgh, , United Kingdom
Glasgow, , United Kingdom
Hull, , United Kingdom
Leeds, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Newport, , United Kingdom
Nottingham, , United Kingdom
Shrewsbury, , United Kingdom
Taunton, , United Kingdom
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GT1105
Identifier Type: -
Identifier Source: secondary_id
GTC-80-203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.